Medicinova (MNOV) Net Margin (2012 - 2025)

Medicinova's (MNOV) quarterly Net Margin came in at 1841.01% in Q4 2025, up 29.37% on a QoQ basis from 2606.72% in Q3 2025.

Medicinova (MNOV) Net Margin (2012 - 2025) Analysis & Trends

Medicinova (MNOV) has 5 years of Net Margin data on file, last reported at 1841.01% in Q4 2025.

On a quarterly basis, Net Margin changed N/A year-over-year to 1841.01% in Q4 2025; TTM through Dec 2025 was 3142.14%, a N/A change from a year earlier, with the FY2025 full-year figure at 2312.58%, changed N/A from the prior year.
Net Margin for Q4 2025 stood at 1841.01%, up from 2606.72% in the prior quarter.
Over the last five years, Net Margin for MNOV reached as high as 5.66% in Q1 2021 and fell as low as 12464.77% in Q3 2021.
Historically, Net Margin has averaged 3291.35% across 3 years, with a median of 2223.86% in 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	15.02%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	34.53%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	20.17%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	30.33%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Medicinova	64.48 Mn	64.48 Mn	4,754.00	-1,841.01%

Download Data